Osteoporosis is a common aging-related disease diagnosed primarily using bone mineral density (BMD). We assessed genetic determinants of BMD as estimated by heel quantitative ultrasound in 426,824 individuals, identifying 518 genome-wide significant loci (301 novel), explaining 20% of its variance. We identified 13 bone fracture loci, all associated with estimated BMD (eBMD), in ~1.2 million individuals. We then identified target genes enriched for genes known to influence bone density and strength (maximum odds ratio (OR) = 58, P = 1 × 10 −75 ) from cell-specific features, including chromatin conformation and accessible chromatin sites. We next performed rapid-throughput skeletal phenotyping of 126 knockout mice with disruptions in predicted target genes and found an increased abnormal skeletal phenotype frequency compared to 526 unselected lines (P < 0.0001). In-depth analysis of one gene, DAAM2, showed a disproportionate decrease in bone strength relative to mineralization. This genetic atlas provides evidence linking associated SNPs to causal genes, offers new insight into osteoporosis pathophysiology, and highlights opportunities for drug development.
O steoporosis is a common, aging-related disease characterized by decreased bone strength and consequent increased fracture risk 1 . BMD, the most clinically relevant risk factor when diagnosing osteoporosis, is highly heritable 2 and is a strong risk factor for fracture 3 . BMD genome-wide association studies (GWASs) have demonstrated that it is a highly polygenic trait 2 , and the known genetic determinants of fracture all act through BMD. Recently, we identified 203 loci associated with eBMD by measuring quantitative heel ultrasound, explaining 12% of its variance, demonstrating this polygenicity 4 . eBMD is predictive of fracture and is highly heritable (50-80%) [5] [6] [7] [8] [9] . While BMD measured from dual-energy X-ray absorptiometry (DXA) scanning is most often used in clinical settings, our recent eBMD GWAS identified 84% of all currently known genomewide significant loci for DXA-derived BMD 4 , and effect sizes were concordant between the two traits (Pearson's r = 0.69 for lumbar spine and 0.64 for femoral neck) 4 . The largest GWAS to date for DXA-derived BMD measures contained only 66,628 individuals 10 .
Both ultrasound and DXA-derived BMD are strongly associated with fracture risk, where a standard deviation decrease in either metric is associated with an approximate 1.5-fold increase in osteoporotic fracture risk 3, 11 .
Little is known about how to reliably map associated loci to their causal genes. However, highly polygenic traits such as bone density allow empirical testing of which methods link associated SNPs to genes enriched for causal proteins. Causal proteins can be identified in human clinical trials when their manipulation by medications leads to changes in BMD 2 . Another source of causal proteins is Mendelian genetic conditions, which may constitute human knockouts and strongly implicate key genes that underlie bone physiology 12 . Given a sufficient number of associated loci, different genomic characteristics that link a SNP to these causal proteins can be tested, including genomic landscape characteristics such as cell-specific 3-dimensional (3D) contact domains, cell-specific open chromatin states, physical proximity, and the presence of associated coding variation. Furthermore, knockout mice generated
An atlas of genetic influences on osteoporosis in humans and mice
Articles Nature GeNetics by large-scale studies can be used to identify genes whose deletion results in an abnormal mouse skeletal phenotype. Rapid-throughput phenotyping data can then be used to determine whether outlier bone phenotypes are enriched in mice harboring deletions of genes identified by GWAS in humans.
Here we present a comprehensive investigation of genetic influences on eBMD and fracture in humans and mice. We undertook an eBMD GWAS of 426,824 individuals in the UK Biobank, identifying 301 novel loci, which explain 20% of its variance, and identified genetic determinants of fracture in up to 1.2 million individuals, combining the UK Biobank and 23andMe cohorts. We then assessed SNP-level and genomic landscape characteristics, mapping associated SNPs to genes enriched for known bone density proteins. Identified target genes were enriched up to 58-fold for known causal genes and for genes differentially expressed in vivo in osteocytes compared with bone marrow cell models. Finally, we asked whether deletion of GWAS-identified genes results in skeletal abnormalities in vivo by undertaking rapid-throughput phenotyping of knockout mice, which included 126 target genes. Mice harboring deletions of these 126 genes were enriched for outlier skeletal phenotypes. A convergence of human and mouse genetics, bone cell expression, and cell culture data pointed to a role for DAAM2 in osteoporosis. We found that mice with a hypomorphic Daam2 allele had marked decreases in bone strength and increases in cortical bone porosity. Finally, CRISPR-Cas9-mediated edits of DAAM2 in osteoblast cell lines demonstrated a reduction in mineralization compared with that in unedited cells.
These newly identified loci will empower future clinical and pharmacological research on osteoporosis, spanning from a better understanding of its genetic susceptibility to, potentially, biomarker discovery and drug targets.
Results
GWAS for eBMD and fracture. We selected 426,824 UK Biobank full-release white British individuals (55% female) for an eBMD GWAS (Methods, Supplementary Table 1 , and Supplementary  Fig. 1 ). We analyzed 13,737,936 autosomal and X-chromosomal SNPs for their association with eBMD. Although there was substantial inflation of the test statistics relative to the null for eBMD (genomic inflation factor (λ GC ) = 2.26, Supplementary Fig. 2 ), linkage disequilibrium (LD) score regression indicated that most of the inflation was due to polygenicity rather than population stratification (LD score regression intercept = 1.06 (0.063), ratio = 0.017 (0.018)).
We identified 1,103 conditionally independent signals (423 novel) at genome-wide significance (P < 6.6 × 10 −9 , Methods) mapping to 515 loci (301 novel; Fig. 1 and Supplementary Table 2 ). Of the conditionally independent lead SNPs per locus, 4.6% were rare, having a minor allele frequency (MAF) ≤ 1%, whereas 9.3% were low frequency (MAF ≤ 5% but > 1%), and 86.1% were common (MAF > 5%; Supplementary Fig. 3 shows the relationship between MAF and absolute effect size). The average absolute conditional effect sizes for these three categories of SNPs were 0.14, 0.04, and 0.02 standard deviations, respectively. The total variance explained by conditionally independent genome-wide significant eBMD lead SNPs was 20.3%. When partitioning the variance explained by these lead SNPs into three MAF categories, we found that rare variants explained 0.8% of the variance in eBMD, whereas low-frequency and common variants explained 1.7% and 17.8% of the variance, respectively. We found strong correlations between eBMD effect sizes with UK Biobank interim release effect sizes (coefficient of correlation (r) = 0.93, Supplementary Fig. 4 and Supplementary  Table 3 ). Additionally, we performed sex heterogeneity analyses to investigate whether the genetic etiology of eBMD differed between the sexes (Supplementary Note, Supplementary Fig. 6 , and Supplementary Tables 5-7 ). The total number of genome-wide significant conditionally independent signals becomes 1,106 (518 loci) when including these analyses; however, we focus on results from the main GWAS for this study.
We identified 416,795 UK Biobank participants (n cases = 53,184 (60% female) and n controls = 373,611 (54% female)) for a GWAS of fracture risk ( Supplementary Table 1 ). We assessed 13,977,204 autosomal and X-chromosomal SNPs and identified 14 conditionally independent signals associated with fracture mapping to 13 loci (Supplementary Table 4 and Supplementary Fig. 5 ). Once again, we observed statistic inflation (λ GC = 1.15). However, this inflation was also probably due to polygenicity rather than population stratification (LD score regression intercept = 1.00 (0.008), ratio = 0.017 Articles Nature GeNetics (0.038)). Conditionally independent genome-wide significant-lead SNPs were tested for replication in a cohort of research participants from 23andMe, Inc., a personal genetics company (n cases = 367,900 and n controls = 363,919). All 14 SNPs showed strong evidence of replication ( Supplementary Table 4 ). All genome-wide significant fracture SNPs were also found to be genome-wide significantly associated with eBMD in the expected direction of effect (that is, alleles lowering eBMD increased fracture risk). Furthermore, there was a highly negative correlation between SNP effect sizes on eBMD and fracture (r = − 0.77 (− 0.79, − 0.74); Supplementary Fig. 4 ).
Fine-mapping associated loci. To map SNPs to potentially causal genes, we first refined associated SNPs at each locus using two statistical fine-mapping methods, GCTA-COJO 13, 14 and FINEMAP 15 . These methods identify SNPs based on their conditional independence and posterior probability for causality, respectively. We generated SNP sets for each genome-wide significant autosomal locus by identifying conditionally independent lead SNPs or SNPs having a high posterior probability of causality, as determined by log 10 Bayes factor > 3 ( Fig. 2a ; we report all SNPs with log 10 Bayes factor > 2 in Supplementary Tables 8-10 ). Here we refer to the set of 'fine-mapped SNPs' as SNPs achieving either conditional independence or a high posterior probability for causality; on average, we observed two conditionally independent SNPs and five SNPs with a log 10 Bayes factor > 3 per locus (Supplementary Note).
Comparing fine-mapped SNPs for biological activity. Given the large number of associated SNPs per locus, downstream analyses should focus on SNPs most likely to be biologically functional. We used accessible chromatin sites surveyed in relevant cellular contexts as a proxy for biological activity. We generated assay for transposase-accessible chromatin using sequencing (ATAC-seq) maps in the human osteosarcoma cell line SaOS-2, which possess osteoblastic features and can be fully differentiated into osteoblastlike cells. We also analyzed DNase I hypersensitive site (DHS) maps from human primary osteoblasts from the ENCODE project 16 . Both ATAC-seq and DHS data were analyzed using a uniform mapping and peak-calling algorithm (Methods). We then analyzed fine-mapped SNPs for enrichment of these functional signatures relative to all SNPs within 1 Mbp of each genomewide significant association locus. Fine-mapped SNPs, including the set of conditionally independent SNPs and SNPs with log 10 Bayes factors > 3, were strongly enriched for both missense variants in protein coding regions (Supplementary Note and Supplementary Table 11 ) and osteoblast open chromatin sites ( Fig. 3a ). As log 10 Bayes factor increased, fold enrichment increased as well ( Fig. 3b ), indicating that fine-mapped SNPs were highly enriched for genomic signatures of function, which can inform the choice of statistical cutoff for SNP selection in follow-up functional studies.
Mapping fine-mapped SNPs to target genes and enrichment for positive control genes. Human genetic associations have rarely been translated to improved clinical care, primarily because causal genes at associated loci have often not been indisputably identified. We therefore sought to test which genomic features linked associated SNPs to genes known to influence bone biology in humans. We identified proteins whose perturbation through pharmacotherapy 2 or Mendelian disease led to changes in bone density or strength. Mendelian disease genes were defined as monogenic disorders characterized with altered bone mass or abnormal skeletal mineralization, osteolysis and/or skeletal fragility, or osteogenesis imperfecta ( Supplementary Table 12 ) and constitute an informative human knockout resource 17 . We considered such proteins identified through pharmacotherapy or Mendelian disease to be products of 'positive control' genes that are probably critical to bone biology.
Next, we investigated which genomic features linked finemapped SNPs to positive control genes. We tested whether positive control genes were enriched among six types of genomic characteristics that can link a SNP to a gene: (i) genes most proximal to finemapped SNPs; (ii) genes containing fine-mapped SNPs overlapping their gene bodies; (iii) genes containing fine-mapped SNPs coding variants; (iv) genes identified to be in 3D contact with fine-mapped SNPs in human osteoblasts or osteocytes through high-throughput chromatin conformation capture (Hi-C) experiments; (v) the closest gene to fine-mapped SNPs also mapping to ATAC-seq peaks in SaOS-2 cells; and (iv) genes within 100 kbp of fine-mapped SNPs 
Fig. 2 | Fine-mapping SNPs and target gene selection diagram. a,
For each 500-Mbp region around a conditionally independent lead SNP (P < 6.6 × 10 −9 after conditional independence testing; n = 426,824 UK Biobank participants), we applied statistical fine mapping to calculate log 10 Bayes factors (BF) for each SNP as a measure of their posterior probability for causality. Conditional independence testing was implemented using GCTA-COJO 13, 14 , and log 10 Bayes factors were estimated using FINEMAP 15 . SNPs that were conditionally independent lead SNPs or that had log 10 Bayes factors > 3 were considered our fine-mapped SNPs that we then used for target gene identification. P.NI, non-infinitesimal mixed model association test p-value. b, Target Genes were identified if: (1) it was the gene closest to a fine-mapped SNP; (2) A fine-mapped SNP was in its gene body; (3) a fine-mapped SNP was coding; (4) the gene mapped closest to a finemapped SNP that resided in an SaOS-2 ATAC-seq peak; (5) a fine-mapped SNP was present in a Hi-C osteoblast or osteocyte promoter interaction peak, therefore being closer to a target gene in three dimensions than linearly on the genome.
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Nature GeNetics ( Fig. 2b emphasizes the target gene selection; Fig. 4 details this entire pipeline). Coding annotations, ATAC-seq peaks, and Hi-C interaction peaks were not combined but were kept separate to enable different sources of data to provide converging and confirmatory evidence. Distance from a fine-mapped SNP to a gene considered the closer of the 3′ and 5′ ends, not the transcription start site. We named identified genes 'Target Genes' and tested which of these six methods most enriched Target Genes for positive control genes. The set of Target Genes most strongly enriched for positive control genes arose from genes targeted by SNPs that were conditionally independent and by SNPs identified to be plausibly causal with a log 10 Bayes factor > 3 ( Table 1 and Supplementary Table 13 ). This set of Target Genes featured 556 genes total, approximately one per locus. All six methods for linking fine-mapped SNPs to Target Genes yielded strong enrichment for positive control genes. The ORs ranged from 5.1 (95% confidence interval (CI): (3.0, 8.6), P = 1 × 10 −11 ) for Target Genes within 100 kbp of the fine-mapped SNPs to an OR of 58.5 (95% CI: (26.4, 129.31), P = 1 × 10 −75 ) for Target Genes closest to fine-mapped SNPs in osteoblast-derived ATAC-seq peaks (Table 1) . Additionally, we used FUMA 18 to assess which pathways from the WikiPathways 19 database were identified by the set of Target Genes most strongly enriched for positive control genes. We observed that known pathways such as Wnt signaling, endochondral ossification, and osteoclast and osteoblast signaling as well as novel pathways were highlighted by this approach ( Supplementary Fig. 7) .
These results suggest that our Target Gene identification method leads to strong enrichment for positive control genes known to be central to bone biology. Such methods may help to prioritize genes at associated loci for functional testing, which are more likely to influence bone biology and therefore have clinical relevance (full list of mapped Target Genes and the method through which they were identified is presented in Supplementary Table 14 ). Comparison of eBMD-associated SNPs in terms of enrichment for DHSs from primary osteoblasts, and ATAC-seq peaks from SaOS-2 osteosarcoma cells. Odds ratios were computed relative to all SNPs at genome-wide significant regions. Enrichments for missense protein coding SNPs are shown as baselines. a, Enrichments for conditionally independent (COJO) or log 10 Bayes factor > 3 (FINEMAP); note the latter set contains nearly twice the number of SNPs. b, Ranking SNPs by log 10 Bayes factor (x axis) showed increasing enrichment. 95% confidence interval (shaded region) was calculated by a two-sided Fisher's exact test. 
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Mapping fine-mapped SNPs to osteocyte signature genes. An alternative method to assess the biological plausibility of Target Genes is to test whether their expression is enriched in bone cells.
Osteocytes are the most abundant cell type in bone and are key regulators of bone mass, bone formation, and bone resorption 20 . We therefore assessed the transcriptomes of primary mouse osteocytes derived from three bone types in vivo 21 . Genes enriched for expression in osteocytes and expressed in all bone types defined an osteocyte transcriptome signature 21 . We then tested which of the methods used to identify eBMD Target Genes resulted in the greatest enrichment for osteocyte-signature genes. We found that Target Genes were strongly enriched for osteocyte signature genes, with ORs for enrichment ranging from 2.1 (95% CI: (1.7, 2.5), P = 2 × 10 −17 ), for Target Genes within 100 kbp of the finemapped SNPs, to 7.4 (95% CI: (3.8, 14.5), P = 5 × 10 −12 ), for Target Genes mapped through fine-mapped coding SNPs (Table 2 and Supplementary Tables 15 and 16 ). This finding again suggests that our methods result in enrichment for biologically relevant genes.
Large-scale high-throughput mouse knockout screening. We investigated whether deletion of Target Genes resulted in enrichment of outlier skeletal phenotypes with the Origins of Bone and Cartilage Disease (OBCD) study (URLs, Supplementary Note). Outlier cortical and trabecular bone phenotypes were more frequent in mice with disruptions of 126 Target Genes compared with 526 unselected knockout lines ( Supplementary Tables 17 and 18 ; OR 3.2 (95% CI: (1.9,5.6), P < 0.0001)). Therefore, enrichment of abnormal skeletal phenotypes in mice with disruption of Target Genes provides clear functional validation that our fine-mapping approach identifies critical and biologically relevant skeletal genes. Our fine mapping in vivo and in vitro data converged to identify DAAM2 as a highly credible and novel osteoporosis gene; therefore, we undertook detailed analyses of mice with a hypomorphic Daam2 allele to illustrate the potential of this approach.
In-depth characterization of DAAM2. Numerous lines of evidence identified DAAM2 as an important gene for further functional investigation. First, a conditionally independent lead SNP, rs2504101, mapped directly to DAAM2 (P conditional = 4.3 × 10 −10 ). Second, fine mapping identified two coding missense variants with high posterior probabilities for causality, rs201229313 in its 19th exon (log 10 Bayes factor = 3.7) and rs61748650 in its 21st exon (log 10 Bayes factor = 2.5). Third, a rare variant, rs772843886, near DAAM2 was suggestively associated with risk of fracture (P = 2 × 10 −3 ). Fourth, the Daam2 tm1a/tm1a mouse was identified as having an outlier skeletal phenotype in our rapid-throughput mouse knockout screening program ( Supplementary Table 17 ). Fifth, although DAAM2 has not previously been implicated in osteoporosis, it has been predicted to have a role in canonical Wnt signaling 22, 23 .
To investigate the role of DAAM2 in bone biology, we first tested its expression in bone cells. We performed RNA-seq and ATAC-seq experiments in four different human osteoblast cell lines and found that it was expressed in all cell lines (Methods and Supplementary  Fig. 8 ). Staining experiments in the SaOS-2 cell line showed that DAAM2 localized specifically in the cell nuclei (Supplementary Figs. 9 and 10). This functional evidence from human bone cells also led us to characterize Daam2 in mouse bone cells. Daam2 was identified as an osteocyte signature gene ( Supplementary Table 16 ) and was expressed in mouse calvarial osteoblasts and bone-marrow-derived osteoclasts ( Supplementary Table 19 ).
Next, using CRISPR-Cas9, we tested the effect of doublestranded breaks (DSBs) in the second exon of DAAM2 in SaOS-2 osteoblast cell lines on bone mineralization (Methods). We found that after 14 days of treatment with osteogenic factors, control cells transfected with the intact plasmid, but not undergoing a DSB of the DAAM2 gene, had a ninefold increase in mineralization. After the introduction of a DSB in the second exon of DAAM2, induced mineralization was severely impaired (Fig. 5 ). These CRISPR-Cas9based findings suggest that DAAM2 influences mineralization capacity in human osteoblasts.
We next analyzed the skeletal phenotypes of Daam2 tm1a/tm1a , Daam2 +/tm1a , and wild-type littermate mice in detail. Adult male Daam2 tm1a/tm1a mice had reduced femur and vertebral bone mineral content (BMC), and male Daam2 +/tm1a and female Daam2 tm1a/tm1a mice also had reduced vertebral BMC. These changes were accompanied by a small reduction in femur length in Daam2 tm1a/tm1a mice (males = 2.7%, females = 3.5%). Despite otherwise normal trabecular and cortical bone structural parameters, cortical porosity was increased in both male and female Daam2 tm1a/tm1a mice ( Supplementary Fig. 11 ).
Consistent with their increased cortical porosity, Daam2 tm1a/tm1a mice had markedly reduced bone strength ( Fig. 6 ) even though all other cortical bone parameters, including BMD, were normal ( Supplementary Fig. 11 ). Bone composition and structure were thus investigated in Daam2 tm1a/tm1a mice by comparing Daam2 tm1a/tm1a mineralization and biomechanical parameters with values predicted by linear regression analysis of over 300 wild-type age-, sex-, and genetic background-matched wild-type controls. Measures of bone composition and structure in Daam2 tm1a/tm1a mice were reduced compared with those of wild-type mice, and vertebral stiffness was > 2 standard deviations below that predicted, even after accounting for reduced BMC ( Fig. 6c and Supplementary Table 20 ).
In additional experiments we observed (Supplementary Note) that measures of bone resorption (TRAP) and formation (P1NP) did not differ between wild-type and Daam2-hypomorphic mice All genes within 100 kbp 6.8 (3.9-11.7) 2.1 × 10 −15
Osteocyte Hi-C interaction gene --Enrichment was calculated with a chi-square test against 19,455 total protein-coding genes.
No positive control genes were identified via osteocyte Hi-C interactions; therefore, we did not calculate its enrichment. Distance to gene was determined using 3′ and 5′ ends, instead of the transcription start site. Enrichment was calculated with a chi-square test against 19,455 total protein-coding genes. Distance to gene was determined using 3′ and 5′ ends, instead of the transcription start site.
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( Supplementary Fig. 12 ) and that male Daam2-hypomorphic mice had decreased mineral content per unit matrix protein and increased carbonate substitution compared with wild-type mice ( Supplementary Fig. 13 ). Taken together, these data suggest that the decreased bone strength in Daam2 tm1a/tm1a mice is not simply a result of abnormal bone turnover, but also a consequence of increased porosity and impaired bone composition and structure. If DAAM2 proves to be a tractable drug target, such an agent would represent a complementary therapeutic strategy for prevention and treatment of osteoporosis and fragility fracture.
While DAAM2 represents a detailed validation of a novel Target Gene, we also highlight five additional eBMD Target Genes, with evidence for association with fracture ( Supplementary  Table 21 ), in the Supplementary Note. These five genes had contrasting abnormalities of bone structure and strength when deleted in mice, emphasizing their functional role in skeletal physiology and importance for further study. These genes (also listed in Supplementary Tables 11 and 17 ) are CBX1 ( Supplementary Fig. 14) , WAC ( Supplementary Fig. 15 ), DSCC1 ( Supplementary Fig. 16 ), RGCC ( Supplementary Fig. 17 ), and YWHAE ( Supplementary  Fig. 18 ). Respective bone composition and structure screens are in Supplementary Figure 19 .
Discussion
In this comprehensive study on the genetic determinants of bone density and fracture in humans and mice, we identified 518 genome-wide significant loci (301 novel) that explain 20% of total eBMD variance. In a meta-analysis of up to 1.2 million individuals, 13 fracture loci were identified, all of which also associated with eBMD. Leveraging the polygenicity of eBMD, we demonstrated strong enrichment for fine-mapped SNPs in bone cell open chromatin. We used fine-mapped SNPs to identify Target Genes strongly enriched for genes with known central roles in bone biology through Mendelian genetics or as targets for clinically validated osteoporosis therapies. High-throughput skeletal phenotyping of mice with deletions of 126 Target Genes found enrichment for outlier skeletal phenotypes compared with 526 unselected lines. Finally, we identified DAAM2 as a protein with critical effects on bone strength, porosity, composition, and mineralization. These findings will enable ongoing and future investigators to better understand genomic characteristics that link fine-mapped SNPs to sets of genes enriched for causal proteins. Furthermore, this comprehensive study of genetic variants associated with osteoporosis will provide opportunities for biomarker and drug development
The polygenicity of eBMD is striking. Few traits and diseases currently have hundreds of loci associated at genome-wide significance 12, 24 . This has led to a large proportion of total eBMD variance being explained by now-known genetic determinants, which will facilitate bone biology studies and enable osteoporosis drug development 25 . Despite the large number of genetic and biological inputs into eBMD determination, pharmacological perturbation of even only one protein identified in our GWAS can have clinically relevant effects. For example, RANKL inhibition has been shown to increase bone density by up to 21% after ten years of therapy 26 . Interestingly, the genetic variants near RANKL have small effects on eBMD. Thus, despite small effect sizes for most identified variants, these do not necessarily reflect effect sizes of protein pharmacological manipulation, because common genetic variants tend to have small effects on protein function, whereas pharmacotherapies tend to have large effects on protein function. Consequently, doseresponse curves describing the effect of small and large genetic perturbations on eBMD are needed to decide which proteins to target for drug development 12 .
Polygenicity improved our statistical power to validate linking of associated loci with potentially causal genes. We found that finemapped SNPs were able to identify Target Genes strongly enriched for positive control genes, particularly when the approach implemented relatively simple strategies (for example, nearest gene), or the gene nearest a fine-mapped SNP in cell-relevant open chromatin. We also observed that fine-mapped SNPs were often in 3D contact with Target Genes in human osteoblasts and osteocytes. These data, surveying many genomic landscape features, provide guidance for investigators attempting to identify causal genes from GWASassociated SNPs.
The marked reduction in bone strength in Daam2 tm1a/tm1a mice, despite minimal changes in bone morphology and mineral content, indicated that Daam2 tm1a/tm1a mice have abnormal bone composition and structure explained in part by increased cortical porosity. Furthermore, CRISPR-Cas9-mediated knockouts of DAAM2 in osteoblast cells lines resulted in a marked reduction in inducible mineralization. Few such genes have been identified, and further investigations will be required to determine whether DAAM2 represents a tractable drug target. Nevertheless, previous studies have suggested that DAAM2 indirectly regulates canonical Wnt signaling across several developmental processes 22, 23 . Using different sources of data to identify DAAM2 allowed greater confidence in results. Although each type of data has its own biases, these biases are partially orthogonal, and consequently, concordant evidence from different sources of data increases the quality of the evidence, an approach known as triangulation 27 .
Our fracture GWAS identified 13 loci. These loci also associated with BMD and/or eBMD, highlighting the importance of 
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BMD as a determinant of fracture risk, at least in the age range assessed within the UK Biobank. Although BMD-independent loci for fracture probably exist, they were not identified, despite this well-powered study, suggesting that screening for fracture drug targets should also include understanding the effect of the protein on BMD. This study has important limitations. First, we measured eBMD instead of DXA-derived BMD, which is typically measured in the clinic. Nonetheless, beyond their phenotypic correlation, these two traits have high genetic concordances in terms of their genome-wide significant loci, suggesting that underlying biological properties of these two traits are similar. Importantly, eBMD is a strong predictor of fracture risk in its own right and contributes to risk assessment over and above DXA-derived BMD at the hip 28 . While our Target Gene approach identified a set of candidate genes enriched for genes with known effects on bone density, it is important to note that there is no gold-standard set of genes known to influence BMD. Our rapid-throughput mouse knockout program is ongoing and will investigate many of the Target Genes implicated by our study. Further efforts will be required to functionally validate-or exclude-these genes for effects on bone biology. Our Target Gene approach did not include human gene expression quantitative trait loci (eQTL) data. This is because the largest available eQTL experiments for human osteoblasts involve only 95 individuals 29 , and larger sample sizes with RNA-seq data will be required to link fine-mapped SNPs to genes. Finally, this work was limited to individuals of white British genetic ethnicity, leaving the effect of most genome-wide significant SNPs in other populations to be assessed. It is likely that ongoing studies in non-British populations will address this question.
In summary, we have generated an atlas of genetic influences on osteoporosis in humans and mice. We have more fully described the genetic architecture of eBMD and fracture and identified Target Genes strongly enriched for known roles in bone biology. We used human and mouse genetics, functional genomics, and genome editing to demonstrate the relevance of this approach, formally known as triangulation 27 , by identifying DAAM2. Disruption of DAAM2 in mice led to increased cortical porosity and marked bone composition and strength reduction and decreased mineralization in human osteoblasts. We expect these Target Genes to include new drug targets for the treatment of osteoporosis, a common disease for which new therapeutic options are a priority. Fracture cases were identified using two mutually non-exclusive methods: Hospital Episodes Statistics linked through NHS Digital (URLs), with a hospital-based fracture diagnosis irrespective of mechanism within the primary (n = 392,292) or secondary (n = 320,448) diagnosis field, and questionnairebased self-reported fracture within the past five years (n = 501,694). We defined a set of International Classification of Diseases codes, 10th revision (ICD10), to separate fracture cases from controls with the Hospital Episodes Statistics data. We excluded fractures of the skull, face, hands and feet, pathological fractures due to malignancy, atypical femoral fractures, periprosthetic, and healed fracture codes. A full list of ICD10 codes used can be found in Supplementary Table 22 . We did not exclude any self-reported fracture cases by fracture site, because participants were only asked if they sustained a fracture at ankle, leg, hip, spine, write, arm, other, or unknown. We identified 20,122 fractures using ICD10 codes and 48,818 using questionnaire-based self-reported data. Descriptive statistics of the cohort, after quality control and ancestry selection, are detailed in Supplementary Table 1 .
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For details on ancestry assignment of UK Biobank participants to white British and the identification of unrelated samples for LD reference estimation and X-chromosome analyses, see the Supplementary Note and Supplementary  Figures 20-22 . Table 1 ). For fracture, a maximum of 426,795 white British individuals, comprising 53,184 fracture cases (60% female) and 373,611 controls (54% female) were analyzed. We note that the sample sizes between the two assessed traits are similar but different, because not all fracture cases and controls had eBMD measured and vice-versa. We tested autosomal genetic variants for association with eBMD and fracture, separately, assuming an additive allelic effect, using a linear mixed non-infinitesimal model implemented in the BOLT-LMM v2 software package 31 to account for population structure and cryptic relatedness. The following covariates were included as fixed effects in all models: age, sex, genotyping array, assessment center, and ancestry informative principal components 1 to 20. Autosomal analysis was restricted to up to 13,977,204 high-quality Haplotype Reference Consortium imputed variants with a MAF > 0.05%, minor allele count > 5, info score > 0.3, genotype hard call rate > 0.95, and Hardy-Weinberg P > 1 × 10 −6 . We also analyzed the association between eBMD and fracture and directly genotyped SNPs on the X chromosome, adjusting for the same covariates, using the Plink2 (October 2017) software package 32 and a nested sample of unrelated participants (n = 362,926 for eBMD and n = 45,087 cases and 317,775 controls for fracture). As the analyses for the X-chromosome data were based on observed genotypes, we excluded SNPs with evidence of deviation from Hardy-Weinberg Equilibrium (P < 1 × 10 −6 ), MAF < 0.05%, minor allele count ≤ 5, and overall missing rate > 5%, resulting in up to 15,466 X-chromosome SNPs for analysis. Heterogeneity in effect size coefficients between sexes was tested in EasyStrata 33 , using Cochran's test of heterogeneity 34 : β i effect size estimates of stratum iSE i standard error of stratum i
Genome
.m Manhattan plots of our genome-wide association scans were generated using the same software. We have previously estimated the genome-wide significance threshold α = 6.6 × 10 −9 for analyzing data from the UK Biobank using the above criteria 4 .
Fracture replication meta-analysis. Fourteen genome-wide significant, conditionally independent lead SNPs identified from our fracture GWAS were tested for replication in the 23andMe cohort. Genetic associations were tested against the fracture phenotype on a set of unrelated individuals of European ancestry. Analyses were adjusted for age, sex, principal components 1 to 5, and the genotyping platform. There were 367,900 cases and 363,919 controls. Meta-analysis of UK Biobank discovery and 23andMe replication data was performed using METAL 35 . In order to compare the effect estimates and standard errors of the UK Biobank discovery and 23andMe replication data, we transformed the UK Biobank discovery effect estimates and standard errors as per the manual specifications in the BOLT-LMM 31 documentation, specifically:
where μ = case fraction and standard errors of SNP effect estimates should also be divided by μ μ − ( *(1 )) .
Approximate conditional association analysis. To detect multiple independent association signals at each of the genome-wide significant eBMD and fracture loci, we applied approximate conditional and joint genome-wide association analysis using the software package GCTA v1.91 (ref. 14 ) . Variants with high collinearity (multiple regression R 2 > 0.9) were ignored, and those situated more than 20 Mbp away were assumed to be independent. A reference sample of 50,000 unrelated white British individuals randomly selected from the UK Biobank was used to model patterns of LD between variants. The reference genotyping dataset consisted of the same variants assessed in our GWAS. Conditionally independent variants reaching genome-wide significance were annotated to the physically closest gene using Bedtools v2.26.0 (ref. 36 ) and the hg19 gene range list (URLs).
Estimation of variance explained by significant variants and SNP heritability.
We estimated the proportion of eBMD phenotypic variance tagged by all SNPs on the genotyping array (that is the SNP heritability) using BOLT-REML 31 and LD score regression 37 . To calculate the variance explained by independent genomewide significant SNPs (that is, all 1,103 genome-wide significant conditionally independent lead SNPs), we summed the variance explained per SNP using the formula: 2p(1 -p)β 2 , where p is the effect allele frequency, and β is the effect of the allele on a standardized phenotype (mean = 0, variance = 1) [38] [39] [40] .
Estimating genomic inflation with LD score regression. To estimate the amount of genomic inflation present in the data that was due to residual population stratification, cryptic relatedness, and other latent sources of bias, we used stratified LD score regression 41 in conjunction with partitioned LD scores that were calculated for high-quality HM3 SNPs derived from a sample of unrelated 1000G-EUR individuals.
Fine-mapping SNPs. Fine-mapped SNPs were defined as those being conditionally independent, as identified by GCTA-COJO or exceeding our threshold for posterior probability of causality, as defined by FINEMAP. Here we describe the generation of this set of fine-mapped SNPs.
First, SNPs were defined as being conditionally independent using GCTA-COJO 13, 14 . We next calculated the posterior probability of causality. To do so, we defined each conditionally independent lead SNP as a signal around which we would undertake posterior probability testing. We used all imputed SNPs within 500 kbp of a conditionally independent lead SNP and treated each signal independently. For details on our application of FINEMAP for statistical fine mapping to calculate log 10 Bayes factors per SNP, see the Supplementary Note. We used a log 10 Bayes factor > 3 threshold to only consider SNPs with the strongest posterior probabilities for causality and SNPs identified as genome-wide significant conditionally independent lead SNPs as fine-mapped SNPs.
RNA sequencing for mouse osteocytes. We performed an analysis of wholetranscriptome sequencing data of three distinct bone types from the mouse skeleton to measure osteocyte expression 4 . The three sites were the tibia, femur and humerus, and in each, the bone marrow was removed (n = 8 per site). The distribution of normalized gene expression for each sample was used to calculate a threshold of gene expression 42 , with genes above this threshold for 8 out of 8 replicates in any bone type deemed to be expressed. Osteocyte-enriched genes were determined by comparing the transcriptomes of matched bone sample controls, one with the marrow removed and the other with the marrow left intact (n = 5 per site). Genes significantly enriched in osteocytes and expressed in all bone types were defined as osteocyte transcriptome signature genes.
Mapping accessible chromatin. ATAC-seq libraries were generated by the McGill University and Genome Quebec Innovation Centre on 100,000 SaOS-2 cells, using a modified protocol of that previously described 43 . The modifications included: reducing the transposase reaction volume from 50 µ l to 25 µ l, increasing the using the osteocyte signature gene set (n = 1,240) instead of the positive control set, to calculate the odds of Target Genes being active in the osteocyte. For details on the Target Gene pathway analyses using FUMA 18 , see the Supplementary Note. CRISPR-Cas9 methods. SaOS-2 cells were obtained from ATCC (#ATCC HTB-85) and cultured in McCoy5A medium (ATCC) supplemented with 15% of FBS (Wisent Inc) and 1% of penicillin and streptomycin (Wisent Inc.) according to the manufacturer's instructions. Three different guide RNAs (gRNA) targeting the second exon of DAAM2 were cloned in the plasmid pSpCas9(BB)-2A-GFP (PX458), which was a gift from F. Zhang (Broad Institute, Cambridge, MA, USA) (Addgene plasmid #48138) 56 . For gRNA sequences, see Supplementary Note. We observed that the cutting frequency determination scores 57 for each gRNA was < 0.1; therefore, we did not consider off-target effects to merit testing 58 . The construct plasmids were purified using the QIAGEN filter midi prep kit (QIAGEN #12243) according to manufacturer instructions. SaOS-2 cells were cultured to 80% confluence in a 100-mm 2 petri dish. Cells were then transfected with one of the three different plasmids generated, or with the intact plasmid as a control, using TransIT LT1 transfection reagent (Mirus #MIR2304) with a reagent-to-DNA ratio of 3:1. After 48 h post-transfection, GFP-positive cells were sorted using FACS in a single-cell model. The remaining colonies were expanded and then assessed for the presence of DAAM2 protein using immunofluorescence technique (anti-DAAM2, Sigma-Aldrich #HPA051300). For PCR primers designed against regions of DAAM2 flanking the three gRNA target sequences to generate 355 bp amplicons, see the Supplementary Note. PCR products of the identified clones were sequenced using MiSeq (Genome Quebec). For DAAM2 western blots that show DAAM2 protein expression reduced to 17.5% and 33.5% in the gRNA1 and gRNA2 edited clones ( Supplementary Fig. 23 ), respectively, see the Supplementary Note.
To induce mineralization ( Fig. 5 ), cells were then cultured to 90% confluence in a 6-well plate and then treated, or left untreated for control, with osteogenic factors (ascorbic acid 50 µ g/ml and β -glycerophosphate 10 mM). Fresh media containing osteogenic factors was added every 2-3 d over 13 d. At day 14, mineralization was quantified using the osteogenesis assay kit according to manufacturer instructions (Millipore #ECM815). The Alizarin red concentration (µ M) was normalized with the protein content assessed in the media in each culture (Pierce BCA Protein assay kit; Thermo Fisher #23227). Supplementary Table 18 .
Rapid-throughput mouse knockout program. For specifics on the Origins of Bone and Cartilage Disease (OBCD) high-throughput phenotyping, see the Supplementary Note and
Daam2-knockout mice. Mouse studies undertaken at the Garvan Institute of Medical Research (Darlinghurst, New South Wales, Australia) were approved by the Garvan Institute/St Vincent's Hospital Animal Ethics Committee in accordance with New South Wales (Australia) State Government legislation. Daam2 tm1a(KOMP)Wtsi mice (designated Daam2 tm1a/tm1a ) were obtained from the Wellcome Trust/Sanger Institute (Cambridge, UK), where the mice were generated as part of the International Mouse Phenotyping Consortium (URLs) using ES cells produced by the Knockout Mouse Project (URLs). The Daam2 gene in these mice was disrupted by a cassette containing an insertion with an additional splice acceptor site between exons 5 and 6 (URLs). The success of this strategy was confirmed with an 80% knockdown of Daam2 in Daam2 tm1a/tm1a and 50% knockdown in Daam2 +/tm1a . Age-and sex-matched 16-week old mice were used for detailed skeletal phenotyping, as described above.
For details on RNA-seq for mouse calvarial osteoblasts, in vitro osteoblast mineralization, in vitro assays of osteoclast formation, the detection of serum markers of bone resorption and formation, and for Fourier-transform infrared spectroscopy analyses, see the Supplementary Note. 
Data availability
Human genotype and phenotype data on which the results of this study were based are available upon application from the UK Biobank (http://www.ukbiobank. ac.uk). GWAS summary statistics for eBMD and fracture can be downloaded from the GEFOS website (http://www.gefos.org/). RNA-seq and ATAC-seq data generated for human osteoblast cell lines, including re-called DHS peaks from human primary osteoblasts, can be downloaded from the Gene Expression Omnibus (accession number GSE120755). Mouse phenotype data are available online from the IMPC (http://www.mousephenotype.org) and OBCD (http://www. boneandcartilage.com). transposase concentration from 1× to 40× , and using 12 cycles of PCR to enrich each library. Libraries were quantified by Q-PCR, Picogreen, and LabChip and were then sequenced on the Illumina HiSeq 4000 (pair-ended 125-bp sequences) using the Nextera sequencing primers. DNase-sequencing data from primary osteoblast samples 16 were obtained from ENCODE (URLs) under accessions ENCLB776DWN and ENCLB906BCL. Reads were processed using a uniform pipeline to produce both ATAC-seq and DNase-seq peaks. Illumina adapters were trimmed using Trimmomatic v. 0.36(ref. 44 ). Reads were aligned to the hg38 human reference using BWA v.0.7.15 (ref. 45 ). Peak calling was performed using hotspot2 (URLs) with a cutoff of 1% false discovery rate and converted to hg19 reference coordinates using UCSC liftOver (URLs).
References
RNA sequencing for human osteoblast cell lines. RNA library preparations were carried out on 500 ng of RNA from SaOS-2, U2OS, MG63, and HOS cells with RNA integrity number (RIN) > 7 using the Illumina TruSeq Stranded Total RNA Sample preparation kit, according to manufacturer's protocol. Final libraries were analyzed on a Bioanalyzer and sequenced on the Illumina HiSeq 4000 (pair-ended 100-bp sequences). Raw reads were trimmed for quality (phred33 ≥ 30) and length (n ≥ 32), and Illumina adapters were clipped off using Trimmomatic v. 0.35 (ref. 44 ). Filtered reads were aligned to the GRCh37 human reference using STAR v. 2.5.1b 46 . Raw read counts of genes were obtained using HTseq-count v.0.6.1 (ref. 47 ).
High-throughput chromosome conformation capture. Hi-C was performed on primary human osteoblasts and osteocytes from human bone biopsies of nonfracture subjects. Hi-C libraries were prepared as described previously 48 . Instead of using HindIII restriction enzyme, we used DpnII (ref. 49 ), which increased coverage and insensitivity of CpG methylation 50 . The Hi-C libraries were sequenced on Illumina HiSeq 4000 instruments to 2 billion pair-end reads. Replicates of osteoblasts and osteocytes were independently generated and sequenced. HiC-Pro was used to process the HiC-Pro pipeline 51 , beginning with aligning each read end to hg38 reference genomes. The chimeric read ends were filtered to keep only 5′ alignments with MAPQ > 10, then read ends were paired and deduplicated. Contact matrices were constructed, and significant interactions were estimated with Homer 52 , GOTHiC 53 , and Juicer 54 . We defined significant interactions as P < 1 × 10 −15 (comparing observed interactions to estimated expected interactions and taking into account DNA fragment size, GC content, and other genomic features). Only interaction pairs that were significant (P < 1 × 10 −15 ) from all three tools were considered significant. The resolution of Hi-C interactions was from 1.5 to 2 kbp, with an average of 1.8 kbp. ATAC-seq experiments were also performed in primary osteoblasts and osteocytes that were used for Hi-C experiments. We only considered and reported chromatin interactions that mapped to open chromatin.
Target Gene identification. We identified Target Genes for the autosomal finemapped sets by annotating fine-mapped sets of SNPs to the closest protein-coding gene, making additional note if the SNP mapped directly to the gene's introns or exons or was coding. We identified Target Genes on the X chromosome by the closest gene to a conditionally independent lead SNP, as we did not calculate log 10 Bayes factors for SNPs on the X chromosome. Additionally, we annotated Target Genes that may be functional in bone cells by marking which fine-mapped SNPs mapped to open chromatin in human bone cells, identified by SaOS-2 ATAC-seq peaks, and we mapped chromosomal positions of fine-mapped SNPs to significant Hi-C interactions of primary osteoblast and osteocytes. When the interaction chromatin mapped to multiple isoforms of protein coding genes, we selected the one with the most significant interaction (usually with highest interaction counts). When the interaction chromatin mapped to multiple bins, we selected the one(s) with looping domains. We further annotated Target Genes using the osteocyte signature gene set where genes within this set are enriched for osteocyte activity 4 .
Target Gene enrichment analyses. We performed a series of enrichment analyses by calculating the odds of Target Genes being either positive control genes or osteocyte signature genes. We identified a set of 57 proteins whose perturbation through pharmacotherapy 2 or Mendelian disease leads to changes in bone density, monogenic disorders presenting with abnormal skeletal mineralization or low bone mass, osteolysis and/or skeletal fragility, and osteogenesis imperfecta and abnormal skeletal mineralization 17 ( Supplementary Table 12 ). For all protein-coding genes in the genome, which were identified using refGene 55 (n = 19,455), we annotated whether they were found to be Target Genes and/or positive control genes. These annotations allowed us to construct contingency tables and calculate an odds ratio for enrichment of Target Genes among positive control genes. We then used Chisquare tests to calculate P values. We used multiple genomic features to test which methods of identifying Target Genes enriched for positive control genes. To do so, we tested whether positive control genes were enriched among targeted genes identified by four different methods: (i) genes that were most proximal to the fine-mapped set SNPs; (ii) genes that contained fine-mapped SNPs overlapping their gene bodies; (iii) genes containing fine-mapped SNPs that are coding variants; (iv) genes identified to be in 3D contact with fine-mapped sets in human osteoblasts or osteocytes through Hi-C experiments; (v) the closest gene to fine-mapped SNPs, which also mapped to ATAC-seq peaks in human osteoblast SaOS-2 cell lines; and (vi) genes within 100 kbp of fine-mapped SNPs (Figs. 2 and 4) . We then repeated this analysis Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
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Field-specific reporting
Please select the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/authors/policies/ReportingSummary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
Drawing upon data from the UK Biobank full release, we applied stringent quality control criteria to select 424,482 participants for GWAS. Participants were selected if they had high-quality quantitative heel ultrasound data or fracture data and if they were of a White British genetic ethnicity. These sample sizes were sufficient for GWAS and represent the largest sample size to-date for any musculoskeletal trait.
Data exclusions We excluded participants if they were missing covariates pertinent to the association testing using pre-determined criteria (i.e. if the data were missing, the participants were not included in the GWAS). This is because participants lacking covariates for association testing cannot be fit properly to our mixed-model approach. We also manually filtered for obvious outliers by observing the distributions of the data and removing individuals far exceeding the tail ends of the data.
Replication
We performed fracture GWAS replication with 23andMe, Inc. We took our top findings from our fracture GWAS and all findings replicated successfully.
Randomization Participants were recruited at various sites through the UK without any selection criteria. We do adjust for genotyping chip in our association studies, as this assignment was not random.
Blinding
Blinding is not relevant to our study as the participants represent the general population of the UK.
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Validation
Anti-DAAM2 antibody from Sigma life science was validated by Human Protein Atlas: "For each antibody, the observed staining in the different cell lines is assigned a validation score based on concordance with available experimental gene/protein characterization data in the UniProtKB/Swiss-Prot database. The validation scores for up to three cell lines are merged into one of the main categories; Supported, Approved, or Uncertain, to represent the overall antibody staining in all analyzed cell lines. Anti-DAAM2 antibody is Approved meaning that one/multiple location(s) with no available experimental gene/protein characterization data and/or one/multiple location(s) where experimental gene/protein characterization data is partly supporting and partly conflicting."
Goat anti-rabbit IgG Alexa Fluor 488 was validated by Abcam using immunofluorescence of HeLa cells stained with Anti-alpha Tubulin antibody [DM1A] and a loading Control (ab7291).
